Works matching IS 09024441 AND DT 2022 AND VI 108 AND IP 1


Results: 11
    1
    2
    3
    4
    5
    6

    Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group.

    Published in:
    European Journal of Haematology, 2022, v. 108, n. 1, p. 34, doi. 10.1111/ejh.13709
    By:
    • Gregersen, Henrik;
    • Peceliunas, Valdas;
    • Remes, Kari;
    • Schjesvold, Fredrik;
    • Abildgaard, Niels;
    • Nahi, Hareth;
    • Andersen, Niels Frost;
    • Vangsted, Annette Juul;
    • Klausen, Tobias Wirenfeldt;
    • Helleberg, Carsten;
    • Carlson, Kristina;
    • Frølund, Ulf Christian;
    • Axelsson, Per;
    • Stromberg, Olga;
    • Blimark, Cecilie Hveding;
    • Crafoord, Jacob;
    • Tsykunova, Galina;
    • Eshoj, Henrik Rode;
    • Waage, Anders;
    • Hansson, Markus
    Publication type:
    Article
    7
    8

    Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics.

    Published in:
    European Journal of Haematology, 2022, v. 108, n. 1, p. 73, doi. 10.1111/ejh.13706
    By:
    • Richardson, Paul G.;
    • Schjesvold, Fredrik;
    • Weisel, Katja;
    • Moreau, Philippe;
    • Anderson, Larry D.;
    • White, Darrell;
    • Rodriguez‐Otero, Paula;
    • Sonneveld, Pieter;
    • Engelhardt, Monika;
    • Jenner, Matthew;
    • Corso, Alessandro;
    • Dürig, Jan;
    • Pavic, Michel;
    • Salomo, Morten;
    • Beksac, Meral;
    • Oriol, Albert;
    • Lindsay, Jindriska;
    • Liberati, Anna Marina;
    • Galli, Monica;
    • Robak, Pawel
    Publication type:
    Article
    9
    10

    Issue Information.

    Published in:
    European Journal of Haematology, 2022, v. 108, n. 1, p. 1, doi. 10.1111/ejh.13651
    Publication type:
    Article
    11